Fig. 3From: Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer’s disease: a randomized phase 1 studyMean blood concentration–time curves of AD16 in A SAD and B FE groups. Different dosage groups of SAD received a single administration of AD16 tablets. FE study subjects received 20 mg AD16 either in fasted or fed stateBack to article page